Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir-Reference-Cited by-同舟云学术

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rabie Helena¹²,Tikiso Tjokosela³,Lee Janice⁴,Fairlie Lee⁵,Strehlau Renate⁶,Bobat Raziya⁷,Liberty Afaaf⁸,McIlleron Helen³,Andrieux-Meyer Isabelle⁴,Cotton Mark¹²,Lallemant Marc⁴,Denti Paolo³^ORCID

Affiliation:

1. Family Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa

2. Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

3. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

4. Drugs for Neglected Diseases initiative, Geneva, Switzerland

5. Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa

6. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa

7. Enhancing Care Foundation—Durban International Clinical Research, Wentworth Hospital, Durban, South Africa

8. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa

Abstract

In children requiring lopinavir coformulated with ritonavir in a 4:1 ratio (lopinavir-ritonavir-4:1) and rifampin, adding ritonavir to achieve a 4:4 ratio with lopinavir (LPV/r-4:4) overcomes the drug-drug interaction. Possible drug-drug interactions within this regimen may affect abacavir concentrations, but this has never been studied. Children weighing <15 kg needing rifampin and LPV/r-4:4 were enrolled in a pharmacokinetic study and underwent intensive pharmacokinetic sampling on 3 visits: (i) during the intensive and (ii) continuation phases of antituberculosis treatment with LPV/r-4:4 and (iii) 1 month after antituberculosis treatment completion on LPV/r-4:1.

Funder

Drugs for Neglected Diseases initiative

National Research Foundation

Wellcome Trust

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01923-19

Reference43 articles.

1. World Health Organization. 2019. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. World Health Organization, Geneva, Switzerland.

2. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13);Bergshoeff A;Antivir Ther,2005

3. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months

4. Western Cape Health Department. 2018. The Western Cape consolidated guidelines for HIV treatment: prevention of mother- to- child transmission of HIV (PMTCT), children, adolescents and adults (amended version). Western Cape Health Department, Cape Town, South Africa.

5. Low Incidence of Abacavir Hypersensitivity Reaction Among African Children Initiating Antiretroviral Therapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in Pharmacometrics Implementation and Regulatory Integration in Africa: A Systematic Review;Clinical Pharmacology & Therapeutics;2024-08-20

2. Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands;Journal of the Pediatric Infectious Diseases Society;2023-10-05

3. Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis;Frontiers in Pharmacology;2021-10-08

4. Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications;British Journal of Clinical Pharmacology;2021-08-12

5. Abacavir Dosing in Neonates from Birth to 3 Months of Life;SSRN Electronic Journal;2021